In the present study, we conducted a multicenter, prospective phase 2 study to evaluate the primary prophylactic effect of pegylated G-CSF for reducing the incidence of severe neutropenia and febrile neutropenia in patients with RRMM treated with Pd or PCd. Here, CSF3 is linked to neutropenia.